



ASX Announcement

6 February 2026

## Atomo secures Australian order for supply of HIV Self-Tests

- **Order worth ~\$630k for the NAPWHA run HIV Self-Test mail-out program**
- **Government commits to continued funding of key HIV Self-Test programs**

SYDNEY, Australia 6 February 2026 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce securing another purchase order from the National Association of People with HIV Australia (NAPWHA) for approximately A\$630,000 worth of HIV Self-Tests. Atomo considers the revenue from this order to be material.

This order supports ongoing delivery of the national free-to-user HIV Self-Testing program run by NAPWHA<sup>1</sup>. Funded by the Federal Government under new public HIV health policy, the NAPWHA program has proven extremely successful in increasing testing rates among key high-risk cohorts who had not been testing sufficiently or in many cases, not testing at all.

The program is supported by Grindr, the world's largest social networking app for the LGBTIQ+ community, and expansion of the program ensures availability of more HIV self-tests and supports growing awareness around the ability to test for free at home.

Atomo CEO, John Kelly said, "*We have developed a very good working relationship with NAPWHA and other partners here in Australia to ensure that discrete, convenient testing is available to those wishing to know their status. We are delighted to be in a position to provide additional Atomo tests to support this invaluable program*".

---

<sup>1</sup> <https://hivtest.au/>



*This announcement was authorised by the Managing Director and Board.*

For more information, please contact:

John Kelly  
Atomo Diagnostics  
[john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)  
Phone: +61 401 922 279

#### **About Atomo**

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialised several products across international markets and has supply agreements in place for testing applications targeting infectious diseases including sexual health as well as female health.

See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com)

For personal use only